A pipeline of transformational medicines with the development program driven by our team of experts.

    |
  • Pre-clinical
  • |
  • Phase 1
  • |
  • Phase 2
  • |
  • Phase 3
  • |

An oral small molecule, adjunct therapy to insulin in patients with type 1 diabetes (T1D).

Read more

CIN-102 (deudomperidone) is a Dopamine 2/3 antagonist with prokinetic and antiemetic effects.
Read more
CIN-103 is a novel formulation of phloroglucinol modified to enhance the pharmacokinetic properties to sustain the therapeutic exposure for patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Read more

CIN-109, CIN-110, CIN-209 and CIN-210 are series of mono and combination therapies for the treatment of obesity.
Read more

CIN-108 is a small molecule inhibiting defective in cullin neddylation 1 (DCN1) from binding in the pocket where it is necessary to promote neddylation and interfere with the progression of multiple solid tumors.
Read more

Retromer Therapeutics is developing novel medicines to treat neurodegenerative diseases.
Read more

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES